3 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Withdrawn 3 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapy for Progressive and/or Refractory Hematologic Malignancies TAPA-pulsed DC vaccine - Cancer, Hematologic Malignancies | Phase 1 / Phase 2 | Withdrawn | Kiromic BioPharma Inc. | 2017-07-28 | 2018-08-28 | |
| Consolidation Therapy in Patients With Hematologic Malignancies TAPA-pulsed DC vaccine - Cancer, Hematologic Malignancies | Phase 1 / Phase 2 | Withdrawn | Kiromic BioPharma Inc. | 2017-07-28 | 2019-10-14 | |
| Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies BPX-501, AP1903 - Hematologic Malignancies | Phase 1 | Withdrawn | Bellicum Pharmaceuticals | 2016-07-01 | 2020-10-05 |
Hematologic Neoplasms (3) · Neoplasms (2) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Neoplasms by Site (3) · Bone Marrow Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Myeloproliferative Disorders (1)
AP 1903 reagent (1)
Kiromic BioPharma Inc. (2) · Bellicum Pharmaceuticals (1)
United States (2)